Overview

Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)

Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects under fasting condition.
Phase:
Phase 1
Details
Lead Sponsor:
CMP Development, LLC
Treatments:
Digoxin
Spironolactone